These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27405747

  • 61. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
    Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y, KMF investigators.
    Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
    [Abstract] [Full Text] [Related]

  • 62. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
    Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.
    Leukemia; 2016 Apr; 30(4):995-8. PubMed ID: 26271606
    [No Abstract] [Full Text] [Related]

  • 63. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Bao L, Lai Y, Liu Y, Qin Y, Zhao X, Lu X, Jiang Q, Lu J, Huang X.
    Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
    [Abstract] [Full Text] [Related]

  • 64. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
    Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.
    Ann Hematol; 2017 Mar; 96(3):441-448. PubMed ID: 27913860
    [Abstract] [Full Text] [Related]

  • 65. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.
    Seckinger A, Salwender H, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde-Rajaratnam M, Beck S, Neben K, Dührig J, Lindemann W, Schmidt-Wolf IGH, Hänel M, Blau IW, Weisel K, Weinhold N, Raab MS, Goldschmidt H, Choon-Quinones M, Hose D.
    Int J Mol Sci; 2024 Jun 11; 25(12):. PubMed ID: 38928138
    [Abstract] [Full Text] [Related]

  • 66. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma.
    Mazur G, Bogunia-Kubik K, Wróbel T, Karabon L, Polak M, Kuliczkowski K, Lange A.
    Immunol Lett; 2005 Jan 31; 96(2):241-6. PubMed ID: 15585329
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.
    Hematol Oncol; 2013 Mar 31; 31(1):41-8. PubMed ID: 22674819
    [Abstract] [Full Text] [Related]

  • 69. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
    Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH.
    Leuk Res; 2013 Sep 31; 37(9):1070-6. PubMed ID: 23816344
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L.
    Eur J Haematol; 2011 Jan 31; 86(1):16-22. PubMed ID: 20942865
    [Abstract] [Full Text] [Related]

  • 74. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.
    Hematol J; 2002 Jan 31; 3(4):185-92. PubMed ID: 12189564
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM, Abdelwahed E.
    Ann Hematol; 2016 Aug 31; 95(8):1315-21. PubMed ID: 27184486
    [Abstract] [Full Text] [Related]

  • 77. DNA repair genes polymorphisms in multiple myeloma: no association with XRCC1 (Arg399Gln) polymorphism, but the XRCC4 (VNTR in intron 3 and G-1394T) and XPD (Lys751Gln) polymorphisms is associated with the disease in Turkish patients.
    Cifci S, Yilmaz M, Pehlivan M, Sever T, Okan V, Pehlivan S.
    Hematology; 2011 Nov 31; 16(6):361-7. PubMed ID: 22183071
    [Abstract] [Full Text] [Related]

  • 78. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J.
    Leuk Res; 2014 Sep 31; 38(9):1048-54. PubMed ID: 25052306
    [Abstract] [Full Text] [Related]

  • 79. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.
    Ann Hematol; 2012 Nov 31; 91(11):1779-84. PubMed ID: 22773209
    [Abstract] [Full Text] [Related]

  • 80. Strong association of interleukin-6 -174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: A case control study.
    Banday MZ, Balkhi HM, Sameer AS, Chowdri NA, Haq E.
    Tumour Biol; 2017 Mar 31; 39(3):1010428317695940. PubMed ID: 28349833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.